The Antibacterial and Anti-biofilm Traits of the Novel BMAP-27-Melittin Conjugated Peptide Nanoparticle Against
Antimicrobial Peptide
BMAP-27
Biofilms
Melittin
Nanoparticles
Streptococcus mutans
Journal
Iranian journal of pathology
ISSN: 1735-5303
Titre abrégé: Iran J Pathol
Pays: Iran
ID NLM: 101515128
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
02
2022
accepted:
30
06
2022
entrez:
17
10
2022
pubmed:
18
10
2022
medline:
18
10
2022
Statut:
ppublish
Résumé
The spread and development of drug-resistant bacterial strains has prompted the hunt for novel antibacterial polypeptides undergoing conformational changes to confer rapid bactericidal effects. The aim of this study was to evaluate the effect of novel BMAP27-Melittin conjugated peptide- nanoparticle (NP) against Sixty subgingival plaque samples were collected, and 39 Thirty-nine infected subjects were reported, including 24 males and 15 females ( BMAP27-Melittin-NP demonstrated significant antibacterial and anti-biofilm effects against clinical isolates of
Sections du résumé
Background & Objective
UNASSIGNED
The spread and development of drug-resistant bacterial strains has prompted the hunt for novel antibacterial polypeptides undergoing conformational changes to confer rapid bactericidal effects. The aim of this study was to evaluate the effect of novel BMAP27-Melittin conjugated peptide- nanoparticle (NP) against
Methods
UNASSIGNED
Sixty subgingival plaque samples were collected, and 39
Results
UNASSIGNED
Thirty-nine infected subjects were reported, including 24 males and 15 females (
Conclusion
UNASSIGNED
BMAP27-Melittin-NP demonstrated significant antibacterial and anti-biofilm effects against clinical isolates of
Identifiants
pubmed: 36247508
doi: 10.30699/IJP.2022.547555.2718
pmc: PMC9508543
doi:
Types de publication
Journal Article
Langues
eng
Pagination
294-302Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Am J Transl Res. 2019 Jul 15;11(7):3919-3931
pubmed: 31396309
Arch Oral Biol. 2015 Aug;60(8):1083-90
pubmed: 25985036
Int J Antimicrob Agents. 2010 Apr;35(4):322-32
pubmed: 20149602
PLoS One. 2015 Jul 13;10(7):e0132512
pubmed: 26168273
Curr Opin Pharmacol. 2006 Oct;6(5):468-72
pubmed: 16890021
J Membr Biol. 1985;87(1):35-44
pubmed: 4057243
Trends Microbiol. 2018 Mar;26(3):229-242
pubmed: 29097091
Molecules. 2022 May 06;27(9):
pubmed: 35566343
Oral Microbiol Immunol. 2004 Apr;19(2):71-6
pubmed: 14871344
Front Biosci. 2004 May 01;9:1267-77
pubmed: 14977543
FEMS Microbiol Lett. 2001 Feb 20;195(2):205-10
pubmed: 11179653
J Pept Sci. 2004 Apr;10(4):204-9
pubmed: 15119592
Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):E5792-E5801
pubmed: 27647919
Int J Nanomedicine. 2021 Jul 20;16:4891-4900
pubmed: 34321877
Saudi Pharm J. 2016 Sep;24(5):515-524
pubmed: 27752223
Pharmaceutics. 2019 Nov 08;11(11):
pubmed: 31717337
Pharmaceutics. 2020 Sep 02;12(9):
pubmed: 32887353
Acta Biomater. 2015 Oct;25:150-61
pubmed: 26210284
Nano Converg. 2018 Dec 12;5(1):38
pubmed: 30539365
Adv Exp Med Biol. 2008;631:178-88
pubmed: 18792689
Antibiotics (Basel). 2021 May 29;10(6):
pubmed: 34072318
Biosci Rep. 2007 Oct;27(4-5):189-223
pubmed: 17139559
J Med Microbiol. 2005 Jul;54(Pt 7):661-665
pubmed: 15947431
Peptides. 2019 Aug;118:170106
pubmed: 31226350
Virulence. 2010 Sep-Oct;1(5):440-64
pubmed: 21178486
J Med Chem. 2014 Dec 11;57(23):9718-39
pubmed: 25207470
Infect Drug Resist. 2018 Jun 01;11:835-847
pubmed: 29910626
Nat Nanotechnol. 2009 Jul;4(7):457-63
pubmed: 19581900
P T. 2015 Apr;40(4):277-83
pubmed: 25859123
Eur J Clin Microbiol Infect Dis. 2014 Apr;33(4):499-515
pubmed: 24154653
Biofouling. 2012;28(10):1033-61
pubmed: 23016989
Nat Rev Dis Primers. 2017 May 25;3:17030
pubmed: 28540937
Proc Soc Exp Biol Med. 1968 Mar;127(3):707-10
pubmed: 4870538